Korean Pharmaceutical Companies Launch New Low-Dose Pitavastatin Combination Therapies for Dyslipidemia Management
核心洞察
Daewoong Pharmaceutical (搜索)'s Barojet (搜索) demonstrated a 43.9% reduction in LDL cholesterol (搜索) at week 8 in phase 3 trials, significantly outperforming pitavastatin monotherapy's 29.1% reduction.
JW Pharmaceutical (搜索) launched Livarozet (搜索) 1/10mg, expanding treatment options for patients requiring low-dose statin therapy or additional LDL cholesterol (搜索) control after monotherapy.
Both companies are targeting low and moderate risk patients, who comprise over 70% of Korea's adult population, with pitavastatin-based combination drugs offering reduced drug interaction risks.
Two major Korean pharmaceutical companies have launched new low-dose pitavastatin combination therapies, marking significant developments in dyslipidemia (搜索) management for patients across different risk categories. The launches come as companies focus on personalized treatment strategies for the substantial population of low and moderate risk patients in Korea.
Daewoong's Barojet Shows Strong Clinical Results
Daewoong Pharmaceutical (搜索) concluded a month-long symposium tour in June 2024 for its new combination drug Barojet (搜索), which contains pitavastatin 1mg and ezetimibe 10mg. The symposium series, held in Busan, Gyeongju, and Seoul, attracted 210 healthcare professionals and presented phase 3 clinical results demonstrating the drug's efficacy.
In a study involving 129 Korean patients with primary hypercholesterolemia (搜索), Barojet (搜索) achieved a 43.9% reduction in LDL cholesterol (搜索) at week 8, significantly outperforming pitavastatin 1mg monotherapy, which achieved only a 29.1% reduction. The results highlight the enhanced lipid-lowering effect of the combination approach.
The symposium emphasized that low and moderate risk patients comprise over 70% of Korea's adult population, making them a critical target group. Healthcare professionals discussed how cardiovascular risk can increase early among patients with prediabetes or metabolic diseases, making stable LDL cholesterol (搜索) management from the outset particularly important.
Safety Profile and Drug Interaction Advantages
Pitavastatin, the main component of both new formulations, was highlighted for its favorable safety profile. The drug demonstrates a low risk of drug-drug interactions via CYP enzyme pathways, making it relatively safe for patients on multiple medications. Compared with other statins, pitavastatin is associated with a lower risk of new-onset diabetes, thereby reducing the burden of blood sugar management.
These characteristics position pitavastatin-based combinations as treatment options that support both achievement of LDL cholesterol (搜索) targets and long-term medication adherence, according to the clinical presentations.
JW Pharmaceutical Expands Dosage Options
JW Pharmaceutical (搜索) launched Livarozet (搜索) 1/10mg in June 2024, adding a low-dose option to its existing Livarozet portfolio. The new formulation contains 1mg of pitavastatin and 10mg of ezetimibe, joining the existing 2/10mg and 4/10mg products to provide healthcare providers with a wider selection of dosage options.
Livarozet (搜索) represents Korea's first dual combination modified new drug for dyslipidemia (搜索), combining pitavastatin's cholesterol production suppression in the liver with ezetimibe's inhibition of cholesterol absorption in the small intestine. The 1/10mg dose can be offered in various clinical scenarios, including for patients who require low-dose statin therapy or those needing further LDL cholesterol (搜索) control after existing monotherapy.
Comprehensive Treatment Strategies
Both companies are developing comprehensive approaches to dyslipidemia (搜索) management. Daewoong Pharmaceutical (搜索)'s symposium covered treatment strategies for various patient groups, from low and moderate risk to very high risk patients, including those with atherosclerotic cardiovascular disease (搜索) and chronic kidney disease (搜索), as well as patients with mixed dyslipidemia (搜索).
For high-risk patients with atherosclerotic cardiovascular disease (搜索) and acute coronary syndrome (搜索), the symposium emphasized the importance of rapidly reaching and maintaining LDL cholesterol (搜索) goals. The company's portfolio includes rosuvastatin and ezetimibe combination (Crezet (搜索)) for these patients, and atorvastatin-based combination drug Litovazet (搜索) for high-risk patients with impaired renal function.
For patients with mixed dyslipidemia (搜索), the pitavastatin and fenofibrate combination drug Baropeno (搜索) was introduced as a treatment strategy offering the potential to lower triglycerides (搜索) and improve HDL cholesterol (搜索) in addition to LDL cholesterol (搜索) reduction.
Digital Health Integration
Daewoong Pharmaceutical (搜索) is integrating digital solutions with its pharmaceutical offerings through the 'Wellcheck' platform, which supports primary care clinics in the 'Primary Care Chronic Disease Management Program.' The platform assists in everything from patient identification to medication and lifestyle management, representing a 'total solution' approach to enhance continuity in chronic disease management.
JW Pharmaceutical (搜索) is conducting patient education through the "Dangbu, Statin" campaign, providing guidance on treatment goals, medication usage, and information regarding adverse reactions to help dyslipidemia (搜索) patients better manage their condition.
Hyungcheol Park, Head of ETC Marketing Division at Daewoong Pharmaceutical (搜索), stated, "Barojet (搜索) offers an effective LDL-C management solution for low and moderate risk patients, while also considering long-term adherence. Daewoong Pharmaceutical will continue to share evidence-based dyslipidemia (搜索) treatment strategies tailored to specific patient groups to provide highly practical treatment options in real-world clinical practice."